1007 North Orange Street
4th Floor
Wilmington, DE 19802
United States
857-444-0553
https://www.ayalapharma.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno:
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Ruth Ben Yakar Ph.D. | Chief Exec. Officer | N/D | N/D | 1970 |
Dr. Stela Gangrenovitch Ph.D. | Co-Founder, Chief Scientist Officer and Director | N/D | N/D | N/D |
Mr. Mark Gengrinovitch LLB | Co-Founder, Chief Financial Officer and Director | N/D | N/D | N/D |
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
L'ISS Governance QualityScore di Ayala Pharmaceuticals, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.